The Healthy Living Toolkit is developed to educate refugees, immigrants, resettlement agencies, clinics, community based organizations, and other service providers on refugee health issues. The toolkit presents material in a culturally appropriate manner and is intended to help health care-related p...rofessionals more effectively assist refugees and immigrants and reduce health disparities among these populations. The toolkit is available in multiple languages
more
Effective implementation of WHO PEN, combined with other very cost effective population-wide interventions, will help even resource constrained settings to attain the global voluntary targets related to reduction of premature mortality and preventionof heart attacks and strokes.
Standard Treatment Guideline
La Lista OMS de verificación de la seguridad del parto es un instrumento destinada a mejorar la calidad de la atención provista a las mujeres y bebés durante el parto. Es una lista estructurada de prácticas esenciales de atención del parto con fundamento científico que se centra en las princip...ales causas de muerte materna, mortinatalidad y muerte neonatal que ocurren en instituciones de salud de todo el mundo. También se ha elaborado una guía de aplicación de la Lista OMS de verificación para ayudar a las instituciones a aplicarla con éxito
more
Prices people pay for medicines.
The World Health Organization (WHO) Global Status Report on Noncommunicable Diseases 2010 projects that noncommunicable diseases (NCDs) will be responsible for over 44 million deaths during the next decade, representing an increase of about 15% since 2010. Most of these deaths will occur in the WHO ...regions of Africa, South-East Asia and the Eastern Mediterranean. In the African Region alone, NCDs will cause around 3.9 million deaths by 2020.
more
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D ac...tivities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.
more
Health Systems in Transition. Vol. 5 No.3 2015
Workshop on PHC Revitalisation in Nepal, April 5-6, 2010
J Nepal Health Res Counc 2013 May;11(24):198-204